UNIVERSITAS
GADJAH MADA
Kardiotoksisitas Antrasiklin pada Pasien Kanker Anak di RSUP Dr.Sardjito
Rama Iqbal Mahendra, Dr. dr. Sri Mulatsih, M.P.H., Sp.A(K), Prof. dr. Indah Kartika Murni, M.Kes, Ph.D, Sp.A(K)
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

F. Conflict of Interest

There are no sponsorship nor conflicts of interest in this study.

G. Acknowledgement

We would like to express our gratitude to the Department of Child Health Sub Division Hemato-Oncology Dr. Sardjito General Hospital for providing permission and data collection.

H. Funding Acknowledgement

This research received no external funding.

I. Ethical Statement

Approval was granted by the Medical and Health Research Ethics Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada – Dr. Sardjito General Hospital (Number: KE/FK/1523/EC/2025).

J. References

1. van Gelder MA, van der Zanden SY, Vriends MBL, Wagensveld RA, van der Marel GA, Codée JDC, et al. Re-Exploring the Anthracycline Chemical Space for Better Anti-Cancer Compounds. J Med Chem. 2023 Aug;66(16):11390–8.
2. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013 Oct;128(17):1927–95.
3. Samosir SM, Utamayasa IKA, Andarsini MR, Rahman MA, Ontoseno T, Hidayat T, et al. Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study. Asian Pac J Cancer Prev. 2021 May;22(5):1407–12.
4. Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med [Internet]. 2020;Volume 7-2020. Available from: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2020.00026
5. Nathan P, Kulkarni K, MacDonald T. Incidence and risk factors of anthracycline-induced cardiotoxicity in long-term survivors of pediatric cancer: A population based cohort study. Pediatr Hematol Oncol J [Internet]. 2022;7(4):136–41. Available from: https://www.sciencedirect.com/science/article/pii/S2468124522002431
6. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol Off J Am Soc Clin Oncol. 1997 Apr;15(4):1544–52.
7. Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013 Dec;112(12):1980–4.
8. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022 Jan;43(4):280–99.
9. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 2008;31(6):459–67.
10. Cai F, Luis MAF, Lin X, Wang M, Cai L, Cen C, et al. Anthracycline-induced cardiotoxicity in the

UNIVERSITAS
GADJAH MADA
Kardiotoksisitas Antrasiklin pada Pasien Kanker Anak di RSUP Dr.Sardjito
Rama Iqbal Mahendra, Dr. dr. Sri Mulatsih, M.P.H., Sp.A(K), Prof. dr. Indah Kartika Murni, M.Kes, Ph.D, Sp.A(K)
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

chemotherapy treatment of breast cancer: Preventive strategies and treatment. Mol Clin Oncol. 2019 Jul;11(1):15–23.
11. Ryan TD, Bates JE, Kinahan KE, Leger KJ, Mulrooney DA, Narayan HK, et al. Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association. Circulation [Internet]. 2025 Apr 15;151(15):e926–43. Available from: https://doi.org/10.1161/CIR.0000000000001308
12. Bates JE, Howell RM, Liu Q, Yasui Y, Mulrooney DA, Dhakal S, et al. Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study. J Clin Oncol [Internet]. 2019 Mar 12;37(13):1090–101. Available from: https://doi.org/10.1200/JCO.18.01764
13. Armenian S, Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am Soc Clin Oncol Educ B [Internet]. 2018;(38):3–12. Available from: https://ascopubs.org/doi/abs/10.1200/EDBK_100015
14. Januchowski R, Wojtowicz K, Andrzejewska M, Zabel M. Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines. Biomed Pharmacother. 2014 Feb;68(1):111–7.
15. Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet [Internet]. 2015;47(9):1079–84. Available from: https://doi.org/10.1038/ng.3374
16. Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, et al. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 2015;16(10):1065–76.
17. Visscher H, Ross CJD, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol Off J Am Soc Clin Oncol. 2012 May;30(13):1422–8.
18. Visscher H, Ross CJD, Rassekh SR, Sandor GSS, Caron HN, van Dalen EC, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013 Aug;60(8):1375–81.
19. El-Demerdash E, Ali AA, El-Taher DEM, Hamada FMA. Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity. J Pharm Pharmacol [Internet]. 2012 Mar 1;64(3):344–52. Available from: https://doi.org/10.1111/j.2042-7158.2011.01413.x
20. Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2016 Sep;34(26):3157–65.
21. van der Pal HJ, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 2010 Jul;170(14):1247–55.
22. Tan VZZ, Chan NM, Ang WL, Mya SN, Chan MY, Chen CK. Cardiotoxicity After Anthracycline Chemotherapy for Childhood Cancer in a Multiethnic Asian Population. Front Pediatr. 2021;9:639603.
23. Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011 Nov;7(4):214–20.
24. Iqubal A, Iqubal MK, Sharma S, Ansari MA, Najmi AK, Ali SM, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. Life Sci [Internet]. 2019;218:112–31. Available from: https://www.sciencedirect.com/science/article/pii/S0024320518308014
25. Stanley CC, Westmoreland KD, Heimlich BJ, El-Mallawany NK, Wasswa P, Mtete I, et al. Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi. Br J Haematol. 2016 Jun;173(5):705–12.